- BRCA1 Reversion Mutation Confers Resistance to Olaparib and Camrelizumab in a Patient with Breast Cancer Liver Metastasis
-
Pan JN, Lei L, Ye WW, Wang XJ, Cao WM
- KMID: 2522098
- J Breast Cancer.
- 2021 Oct;24(5):474-480.
- doi: 10.4048/jbc.2021.24.e39
Reversion mutations are associated with clinical resistance to poly(ADP-ribose) polymerase inhibitors (PARPi). Here, we describe the detection of a BRCA1 reversion mutation in a 39-year-old woman with metastatic breast cancer... -
- CITED
-
- Close
- SHARE
-
- Close
